Skip to main content
. 2021 Aug 12;10(19):6642–6652. doi: 10.1002/cam4.4196

FIGURE 4.

FIGURE 4

Survival outcomes for ASS1‐proficient patients Kaplan–Meier survival estimates for ASS1‐proficient patients screened as part of this study (n = 29) and treated with standard of care cisplatin and pemetrexed chemotherapy and compared to ASS1‐deficient patients receiving ADIPemCis (n = 21)